FINWIRES · TerminalLIVE
FINWIRES

Update: Federal Court Rules Against Coles Group on Price Discounts in ACCC Case

By

(Updates with a statement from Coles in the fifth paragraph and the latest stock move in the last paragraph.)

Australia's Federal Court ruled Thursday that Coles Group (ASX:COL) deceived shoppers by advertising discounts on products that, in many cases, were being sold at higher prices, according to multiple same-day media reports.

The case against Coles was brought by the Australian Competition and Consumer Commission (ACCC) in 2024. The consumer watchdog also filed similar allegations against Woolworths Group (ASX:WOW), with that lawsuit still pending a verdict.

The ACCC said Coles increased prices on certain items for a very short period of time before putting them on a discount, making the promotions illusory in nature. For example, the price of a dog food product sold for AU$4 for almost a year was briefly raised to AU$6 before being discounted to AU$4.50 as part of its "Down Down" price campaign, according to the reports.

"13 of the 14 'Down Down' tickets that were the subject of consideration in the joint liability trial were misleading because the relevant products were not sold at the 'was' price stated on the ticket for a reasonable period," Federal Court judge Michael O'Bryan reportedly said in his decision.

In a statement, Coles said the court found that all price hikes "resulted from supplier cost price increases and were, therefore, commercially justifiable." The case highlights the "need for clear, practical guidance on minimum price establishment periods to ensure the retail industry can avoid unnecessary litigation in future," the company said, adding that it is reviewing the judgment.

The company's shares fell nearly 3% in recent Thursday trade.

Related Articles

Asia

FORE Intelligent Tech Plans to Raise Up to 730 Million Yuan from Share Placement

Zhejiang FORE Intelligent Technology (SHE:301368) plans to raise up to 730 million yuan from share placement plan, according to a Shenzhen bourse filing on Thursday.The company plans to issue up to around 36 million shares to up to 35 investors.Proceeds from the placement will be used to fund the construction of a factory for precision power gears for new energy vehicles, a precision transmission manufacturing plant, and a precision transmission research and development center.The remaining proceeds of up to 200 million yuan will be used to supplement the company's working capital.The Chinese gear manufacturer's shares fell 2% during the midday trade.

$SHE:301368
Asia

Huadong Medicine's Unit Gets Nod to Trial HDM2017 for Injection

Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of HDM2017 for injection, according to a Shenzhen bourse filing on Thursday.The drug is used in combination with Fruquintinib for the treatment of advanced colorectal cancer.

$SHE:000963
Asia

China, US Economic Teams Reach 'Positive Outcome,' Xi Says

Chinese President Xi Jinping said Beijing and Washington's economic teams reached a "generally balanced and positive outcome" during Wednesday's meeting, Xinhua News Agency reported Thursday.Xi made the remarks after welcoming U.S. President Donald Trump in Beijing.U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng met in South Korea on Wednesday, ahead of the high-stakes meeting on Thursday, the BBC reported."Facts have repeatedly proven that there are no winners in a trade war, and the essence of China-US economic and trade relations is mutual benefit and win-win cooperation," Xinhua quoted Xi as saying.

$^SSEC$^SZSE